Terapias biológicas en espondiloartritis: ¿cuándo y cómo?

Dougados, 1991, The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy, Arthritis Rheum, 34, 1218, 10.1002/art.1780341003 Amor, 1990, [Criteria of the classification of spondylarthropathies], Rev Rheum Mal Osteoartic, 57, 85 Clegg, 1999, Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: a Department of Veterans Affairs cooperative study, Arthritis Rheum, 42, 2325, 10.1002/1529-0131(199911)42:11<2325::AID-ANR10>3.0.CO;2-C Van der Heijde, 2006, Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial, Arthritis Rheum, 54, 2136, 10.1002/art.21913 Antoni, 2005, Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial, Ann Rheum Dis, 64, 1150, 10.1136/ard.2004.032268 Mease, 2005, Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial, Arthritis Rheum, 52, 3279, 10.1002/art.21306 Queiro-Silva, 2003, A polyarticular onset predicts erosive and deforming disease in psoriatic arthritis, Ann Rheum Dis, 62, 68, 10.1136/ard.62.1.68 Gladman, 1995, Clinical indicators of progression in psoriatic arthritis: multivariate relative risk model, J Rheumatol, 22, 675 Gladman, 1999, HLA-C locus alleles in patients with psoriatic arthritis (PsA), Hum Immunol, 60, 259, 10.1016/S0198-8859(98)00123-2 Bond, 2007, Predictors for radiological damage in psoriatic arthritis: results from a single centre, Ann Rheum Dis, 66, 370, 10.1136/ard.2006.056457 Amor, 1994, Predictive factors for the longterm outcome of spondyloarthropathies, J Rheumatol, 21, 1883 Hamersma, 2001, Is disease severity in ankylosing spondylitis genetically determined?, Arthritis Rheum, 44, 1396, 10.1002/1529-0131(200106)44:6<1396::AID-ART233>3.0.CO;2-A Gratacos, 2007, Prediction of major clinical response (ACR50) to infliximab in psoriatic arthritis refractory to methotrexate, Ann Rheum Dis, 66, 493, 10.1136/ard.2006.060079 Rudwaleit, 2004, Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis, Ann Rheum Dis, 63, 665, 10.1136/ard.2003.016386 Van der Heijde, 2005, Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT), Arthritis Rheum, 52, 582, 10.1002/art.20852 Brandt, 2003, Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis, Arthritis Rheum, 48, 1667, 10.1002/art.11017 Mease, 2000, Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial, Lancet, 356, 385, 10.1016/S0140-6736(00)02530-7 Marzo-Ortega, 2003, Efficacy of etanercept for treatment of Crohn’s related spondyloarthritis but not colitis, Ann Rheum Dis, 62, 74, 10.1136/ard.62.1.74 Guignard, 2006, Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: a retrospective study, Ann Rheum Dis, 65, 1631, 10.1136/ard.2006.052092 Braun, 2005, Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept, Arthritis Rheum, 52, 2447, 10.1002/art.21197 Smith, 2002, Management of uveitis: a rheumatologic perspective, Arthritis Rheum, 46, 309, 10.1002/art.503 Papp, 2005, A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction, Br J Dermatol, 152, 1304, 10.1111/j.1365-2133.2005.06688.x Leonardi, 2003, Etanercept as monotherapy in patients with psoriasis, N Engl J Med, 349, 2014, 10.1056/NEJMoa030409 Van der Heijde, 2006, Etanercept 50 mg once weekly is as effective as 25 mg twice weekly in patients with ankylosing spondylitis, Ann Rheum Dis, 65, 1572, 10.1136/ard.2006.056747 Jois, 2006, Low-dose infliximab treatment for ankylosing spondylitis –clinically- and cost-effective, Rheumatology (Oxford), 45, 1566, 10.1093/rheumatology/kel156 Keeling, 2006, Prospective observational analysis of the efficacy and safety of low-dose (3 mg/kg) infliximab in ankylosing spondylitis: 4-year followup, J Rheumatol, 33, 558 Descalzo, 2007, Registro Español de Acontecimientos Adversos de Terapias Biológicas en Enfermedades Reumáticas (BIOBADASER): informe de la situación, 26 de enero de 2006, Reumatol Clin, 3, 4, 10.1016/S1699-258X(07)73593-3 Brandt, 2005, Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis, Rheumatology (Oxford), 44, 342, 10.1093/rheumatology/keh475 Baraliakos, 2005, Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab, Arthritis Res Ther, 7, R439, 10.1186/ar1693 Mease, 2004, Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression, Arthritis Rheum, 50, 2264, 10.1002/art.20335 Kavanaugh, 2006, The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1 year, Ann Rheum Dis, 65, 1038, 10.1136/ard.2005.045658 Baraliakos, 2005, Radiographic progression in patients with ankylosing spondylitis after 2 years of treatment with the tumour necrosis factor alpha antibody infliximab, Ann Rheum Dis, 64, 1462, 10.1136/ard.2004.033472 Calabrese, 2004, Safety of antitumour necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B, and HIV infection, Ann Rheum Dis, 63, ii18, 10.1136/ard.2004.028209 Nathan, 2006, Hepatitis B and C virus infections and anti-tumor necrosis factor-alpha therapy: guidelines for clinical approach, J Gastroenterol Hepatol, 21, 1366, 10.1111/j.1440-1746.2006.04559.x Katz, 2004, Outcome of pregnancy in women receiving infliximab for the treatment of Crohn’s disease and rheumatoid arthritis, Am J Gastroenterol, 99, 2385, 10.1111/j.1572-0241.2004.30186.x Salmon, 2006, Are we coming to terms with tumor necrosis factor inhibition in pregnancy?, Arthritis Rheum, 54, 2353, 10.1002/art.22027 Pieringer, 2007, Patients with rheumatoid arthritis undergoing surgery: how should we deal with antirheumatic treatment?, Semin Arthritis Rheum, 36, 278, 10.1016/j.semarthrit.2006.10.003